Browse All

Current Filters

CLEAR FILTER x

TITLE

Overview of the Safety Profile from Efgartigimod Clinical Trials in Participants with Diverse IgG-Mediated Autoimmune Diseases

Author:Gwathmey, Kelly   Broome, Catherine   Goebeler, Matthias   Murai, Hiroyuki   Bata-Csorgo, Zsuzsanna   Newland, Adrian   Ulrichts, Peter   Kerstens, Rene   Guptill, Jeffrey   Agha, Sofiane   Jiang, Ming   Howard, James   

Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

Topic:Autoimmune Neurology  

Program Number:P1.001  

Author Institution:Virginia Commonwealth University, Richmond, VA  Georgetown University, Washington, DC  University Hospital W?rzburg, W?rzburg, Germany  International University of Health and Welfare, Narita, Japan  University of Szeged, Szeged, Hungary  Queen Mary University of London, London, United Kingdom  argenx, Ghent, Belgium  The University of North Carolina at Chapel Hill, Chapel Hill, NC  

Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration

Author:Bril, Vera   Vu, Tuan   Brauer, Edward   Kerstens, René   Howard, James   ADAPT Investigator Study Group, in collaboration with the   

Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

Topic:Autoimmune Neurology  

Program Number:P1.015  

Author Institution:Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, Toronto, ON, Canada  University of South Florida, Morsani College of Medicine, Tampa, FL  argenx, Ghent, Belgium  The University of North Carolina, Chapel Hill, NC  N/A, Yardley, PA